DrugPatentWatch Database Preview
Patent: 5,780,279
» See Plans and Pricing
Summary for Patent: 5,780,279
| Title: | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
| Abstract: | A method for identifying and selecting novel substrates for enzymes is provided. The method comprises constructing a gene fusion comprising DNA encoding a polypeptide fused to DNA encoding a substrate peptide, which in turn is fused to DNA encoding at least a portion of a phage coat protein. The DNA encoding the substrate peptide is mutated at one or more codons thereby generating a family of mutants. The fusion protein is expressed on the surface of a phagemid particle and subjected to chemical or enzymatic modification of the substrate peptide. Those phagemid particles which have been modified are then separated from those that have not. |
| Inventor(s): | Matthews; David J. (San Francisco, CA), Wells; James A. (Burlingame, CA), Zoller; Mark J. (San Francisco, CA) |
| Assignee: | Genentech, Inc. (South San Francisco, CA) |
| Application Number: | 08/418,928 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,780,279
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 004 | 2015-01-23 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 003 | 2015-01-23 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 002 | 2015-01-23 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 001 | 2015-01-23 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | RX | Orphan | search |
| Ethicon, Inc | THROMBIN HUMAN | thrombin human | POWDER, FOR SOLUTION | 125247 | 1 | 2009-09-19 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | search | ||
| Microbix Biosystems | KINLYTIC | urokinase | INJECTABLE;INJECTION | 021846 | 003 | 1978-01-16 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2039-02-26 | DISCN | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 5,780,279
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 967973 | Start Trial |
| World Intellectual Property Organization (WIPO) | 9004788 | Start Trial |
| World Intellectual Property Organization (WIPO) | 9209690 | Start Trial |
| World Intellectual Property Organization (WIPO) | 9711178 | Start Trial |
| United States of America | 2003153003 | Start Trial |
| United States of America | 2006115874 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
